Peptides for Muscle Wasting and Sarcopenia: IGF-1, Follistatin, GH Peptides, and MOTS-c

Sarcopenia — the progressive loss of skeletal muscle mass and function with aging — affects an estimated 10–20% of adults over 60 and rises to 40% or more in those over 80. It is a major driver of falls, frailty, disability, and mortality in older adults. Beyond aging, muscle wasting (cachexia) occurs in cancer, chronic kidney disease, heart failure, HIV, and prolonged immobilization. Despite its clinical importance, pharmacological options for muscle wasting remain limited — a gap that has driven significant research into peptides targeting muscle biology.

This article reviews the most promising peptides for muscle wasting and sarcopenia: IGF-1 and its analogs, follistatin-derived approaches, growth hormone secretagogues, and the mitochondrial peptide MOTS-c.

Biology of Muscle Wasting

Muscle mass is maintained by the balance between protein synthesis (anabolism) and protein breakdown (catabolism). Sarcopenia and cachexia both involve a shift toward net catabolism, driven by:

• Declining anabolic hormones: GH, IGF-1, testosterone, and estrogen all decrease with age
• Inflammatory cytokines: TNF-α, IL-6, and IL-1β directly promote muscle proteolysis via the ubiquitin-proteasome pathway
• Neuromuscular junction decline: Loss of motor neurons and impaired neuromuscular signaling
• Impaired satellite cell function: Muscle stem cells (satellite cells) become less responsive to repair signals
• Myostatin hyperactivity: Elevated myostatin (a TGF-β family member) suppresses muscle protein synthesis
• Mitochondrial dysfunction: Reduced energy production impairs muscle contractility and triggers atrophy signaling

Peptides can intervene at multiple points in this biology.

IGF-1 and Mechano Growth Factor (MGF)

Insulin-like growth factor 1 (IGF-1) is the primary anabolic mediator of growth hormone action in muscle. It promotes muscle protein synthesis via the PI3K/Akt/mTOR pathway and stimulates satellite cell activation, proliferation, and differentiation — essential for muscle repair and growth.

IGF-1 LR3: A long-acting IGF-1 analog with an extended half-life (compared to endogenous IGF-1's minutes-long half-life). Research shows IGF-1 LR3 significantly increases muscle mass and reduces body fat in animal models. It has been studied in humans for muscle-wasting conditions, with evidence of lean mass preservation in GH-deficient adults and cancer patients.

Mechano Growth Factor (MGF): MGF is an IGF-1 splice variant produced in muscle in response to mechanical stress (exercise). It acts as an early anabolic signal before IGF-1 takes over, primarily by activating satellite cells. Pegylated MGF (PEG-MGF) has an extended half-life and is studied for muscle preservation in aging and injury.

Research context: IGF-1 research in sarcopenia supports its role in lean mass maintenance, but concerns about potential effects on cell proliferation (relevant to oncology contexts) have tempered enthusiasm for systemic IGF-1 therapy in healthy aging populations.

Follistatin and Myostatin Inhibition

Myostatin (GDF-8) is a potent negative regulator of muscle growth. Loss-of-function myostatin mutations in animals and rare humans produce dramatic muscle hypertrophy. Inhibiting myostatin is therefore a logical target for treating muscle wasting.

Follistatin: Follistatin is a naturally occurring protein that binds and neutralizes myostatin. Follistatin peptide fragments — particularly follistatin-344 — have been explored for their muscle-promoting effects. Follistatin-315 preferentially affects muscle without the reproductive effects associated with the 344 variant.

Research findings: In non-human primates, follistatin gene therapy produced significant muscle mass increases of 15–25% without the cardiac side effects seen with some other approaches. Human studies are at early stages. Follistatin injection research in cancer cachexia and muscular dystrophy is ongoing.

ACE-031 and similar myostatin traps: Pharmaceutical approaches to myostatin inhibition (soluble ActRII decoy receptors) have been studied in muscular dystrophy and cancer cachexia. While results were mixed in those specific populations, they validated the myostatin pathway as a therapeutic target.

Growth Hormone Secretagogues: CJC-1295, Ipamorelin, and Tesamorelin

Growth hormone declines sharply with aging — an estimated 15% per decade after age 30. Since GH drives IGF-1 production, GH decline contributes substantially to the anabolic deficit of aging. GH peptide secretagogues stimulate endogenous GH pulsatility physiologically.

CJC-1295 with ipamorelin: This is the most commonly used GH secretagogue stack for anti-aging and muscle preservation. CJC-1295 (a GHRH analog) amplifies GH pulse amplitude; ipamorelin (a selective GHRP) stimulates GH release with minimal cortisol or prolactin elevation. Together they produce robust GH/IGF-1 increases.

Clinical evidence in sarcopenia: Studies of GH replacement in GH-deficient adults consistently show improvements in lean mass (2–4 kg over 6–12 months), reductions in fat mass, and improvements in muscle strength. GH secretagogues produce similar though generally more modest effects — appropriate given their physiological, pulsatile GH stimulation rather than pharmacological GH doses.

Tesamorelin: FDA-approved for HIV-associated lipodystrophy, tesamorelin is a stabilized GHRH analog with the strongest clinical evidence base of any GH secretagogue. Studies in older adults without HIV deficiency show improvements in lean mass and physical function with good tolerability. See our tesamorelin peptide guide for details.

GHRP-2: A potent ghrelin receptor agonist with strong GH-releasing effects. More likely to stimulate cortisol and prolactin than ipamorelin, but used in some research protocols for maximum GH output. See our GHRP-2 guide.

For a comparison of GH peptides, see our growth hormone peptides guide.

MOTS-c: Mitochondrial Peptide for Muscle Aging

MOTS-c is a mitochondrial-derived peptide encoded in the mitochondrial genome — a peptide that comes from the organelle responsible for cellular energy production rather than the nuclear genome. This unique origin reflects its role in mitochondrial stress signaling.

Mechanism in muscle: MOTS-c activates AMPK (AMP-activated protein kinase), the cellular energy sensor, and enhances glucose uptake and utilization in skeletal muscle. With aging, muscle mitochondria become less efficient and MOTS-c levels decline. Research in mice shows MOTS-c supplementation in aged animals significantly improves exercise capacity, muscle mass, and metabolic function.

Physical performance: A landmark 2021 study published in Nature Aging demonstrated that MOTS-c injection in old mice improved running capacity and grip strength to near-young levels. The mice also showed reduced muscle atrophy markers and improved mitochondrial biogenesis.

Human relevance: Natural MOTS-c levels in blood correlate with age (lower in older individuals) and physical activity. The peptide's exercise-mimetic effects have led to it being described as a "molecular exercise signal." Human clinical trials are in early stages.

Our MOTS-c peptide guide reviews the full research profile.

Humanin: Mitochondrial Peptide with Muscle Preservation Effects

Humanin is another mitochondrial-derived peptide that has demonstrated muscle-protective effects. It activates STAT3 signaling and has antiapoptotic effects in muscle cells. In aging models, humanin supplementation reduces muscle apoptosis and improves mitochondrial function.

Humanin works synergistically with MOTS-c in some research models. See our humanin peptide guide for a detailed review.

Stacking Approaches for Muscle Wasting

Given the multiple contributing mechanisms, stacking complementary peptides is common in research protocols for sarcopenia:

• CJC-1295/ipamorelin at night for GH restoration and recovery
• BPC-157 for myoprotection and anti-inflammatory support (muscle inflammation drives atrophy)
• MOTS-c for mitochondrial optimization and metabolic support
• Collagen peptides for connective tissue support around aging muscles

The combination of GH secretagogues with resistance training produces synergistic effects — exercise upregulates GH receptors and IGF-1 signaling, amplifying the peptide's anabolic effects. See our peptide stack guide for beginners for foundational principles.

Safety Considerations

GH excess (acromegaly) and IGF-1 excess carry risks including fluid retention, carpal tunnel syndrome, insulin resistance, and potential concerns in oncology patients. GH secretagogues, by stimulating physiological rather than pharmacological GH, carry a substantially lower risk profile than exogenous GH. All protocols should be supervised by a knowledgeable physician and monitored with periodic IGF-1 levels.

Frequently Asked Questions

Q: Can peptides reverse sarcopenia in elderly adults? No peptide reverses the full sarcopenia syndrome. However, GH secretagogues and IGF-1 approaches can preserve or modestly increase lean mass, and MOTS-c shows promising exercise-mimetic effects in aged animals. Combined with resistance training and adequate protein intake, peptides may slow sarcopenia progression meaningfully.

Q: What is the difference between cachexia and sarcopenia? Sarcopenia is the age-related loss of muscle mass and function. Cachexia is a complex syndrome of muscle and fat loss driven by underlying disease (cancer, heart failure, kidney disease) and inflammation. Cachexia involves more aggressive catabolism driven by high TNF-α and IL-6 and is harder to reverse with nutrition or anabolic therapies alone.

Q: Is follistatin legal? Follistatin peptide fragments exist in a research chemical gray area and are not approved for human use. Follistatin is on the WADA prohibited list for competitive athletes. See our WADA banned peptides guide.

Q: How does MOTS-c differ from other peptides? MOTS-c is unique in being encoded in the mitochondrial genome rather than the nuclear genome. It acts as an intracellular signaling molecule and exercise-related hormone, with effects focused on metabolic function and mitochondrial health. Its mechanism is distinct from anabolic peptides like IGF-1 or GH secretagogues.

Q: Does protein intake matter alongside muscle-targeted peptides? Yes, significantly. Peptides that stimulate protein synthesis require adequate substrate — amino acids from dietary protein. Research consistently shows that anabolic interventions produce better outcomes when protein intake is sufficient (1.6–2.2 g/kg body weight). Leucine-rich protein sources (whey, meat) are particularly effective at stimulating mTOR.